Coherus Q3 LOQTORZI rev up 92% YoY to $11.2M; net loss narrows to $44.5M; CHS-114 enters colorectal cancer

Coherus Oncology, Inc.

2025-Q3 EPS reported $1.77 revenue$29,424,000

Net revenue $11.6M (up 90% YoY); LOQTORZI net revenue $11.2M (+12% QoQ, +92% YoY).
GAAP net loss from continuing ops $44.5M (-$0.38/sh) vs $47.6M (-$0.41/sh) prior year.
Non-GAAP net loss $38.9M (-$0.33/sh) vs $40.0M (-$0.35/sh); cash at $191.7M.
CHS-114 Phase 1b/2a enrolling in 4L+ colorectal cancer; initial data expected 2H 2026.
Casdozokitug Phase 2 in 1L HCC enrollment ongoing; first data readout mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.